Shire hits the road to educate on UC

Share this article:

Shire Pharmaceuticals is hitting “the road” as part of a new unbranded education campaign for patients with ulcerative colitis (UC), complete with live events in 10 cities.

Shire developed the “On the Road Again” campaign as a response to results of its series of company-sponsored surveys completed in 2007 illustrating the challenges that exist for UC patients: communication gaps with doctors, medication compliance and other life disruptions. About 700,000 people in the US are afflicted with UC. 

“The ‘On the Road Again' program is intended to empower people with UC across the country and provide them with the knowledge and tools necessary to better manage their disease and regain control of their lives,” explained Mike Yasick, SVP and gastrointestinal global business unit leader at Shire.

The campaign will feature live education event tour stops this spring in Houston, Atlanta, Chicago, New York, Minneapolis, Miami, Philadelphia, Pittsburgh, Los Angeles and Long Island, NY. Each event will include a dietician, a gastroenterologist, a social worker or health psychologist, and an online health information professional. These experts will discuss UC and role of diet, treatment options and building an online UC community, Shire said.

Shire currently markets UC treatments Lialda (mesalamine) and Pentasa (mesalamine).

Shire has also launched www.RoadtoUCLearning.com, an online tour companion that features the “On the Road Again” event schedule, speaker bios, and registration and condition information. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.